STING1 and cancer: The STING agonists TAK‐676, GSK3745417, and MK‐2118 are also in Phase I clinical trials for monotherapy and in combination with anti‐PD‐1 antibodies for advanced cancer (NCT04420884, NCT05424380, and NCT03249792, respectively).